Page 93 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Pain Physician: August 2020 COVID-19 Special Issue 23:S391-S420

Fatigue, pruritus, and ascites improved Serum ALP levels and MRS are 2; data indicate that UC MSC transfusion can and stabilize MRS (2 key parameters for the definition of response to treatment in patients with PBC) during a 48-week follow-up period. MELD improved. Albumin, CHE, and PTA increased showing improved liver functioning. ALT and TBIL levels decreased. AFP levels increased showing Pugh score improved in 10 patients, and a-SMA wer

Findings but no major change in other parameters. significantly reduce the serum ALP levels liver proliferation. Improvement in survival Histological improvements were observed in 6 of the 11 patients (54.5%). The Child the expressions of TGF-b1, collagen-1 and, No change in ALB and TB levels but MELD was lower. MSC transplantation markedly pronounced in the transplantation group,

Condition PBC Acute on chronic liver failure seen. Cirrhosis Alcoholic liver disease Cirrhosis Hepatitis B Cirrhosis

Follow-Up (months) 48 weeks 12 or 18 3 3 12 6

Result Yes Yes Yes No No Yes

Delivery Method IV IV HAI HAI IV HAI

Type of Stem Cell WJ MSC (Pas 4) WJ MSC (Pas 3–4) BM MSC (Pas 4–5) BM MNC BM MSC (Pas 3–4) BM MNC

Number of SC 0.5 million/ kg x 3 doses 0.5 million/ kg x 3 doses 50 million x 2 doses 5 million 195 million 800 million

BMA (mL) NA NA 10–20 103 250 130–150
Table 3 con't. MSC therapy studies treating liver failure.

No. of Patients in Treatment Group 7 43 12 28 14 20

Type of Study Case series PCT Case series RCT RCT PCT

Year 2012 2012 2013 2013 2013 2014

Author Wang et al, J Gastroenterol Hepatol 2013; 28(suppl 1):85-92 Shi et al, Stem Cells Transl Med 2012; 1:725-731 Jang et al, Liver Int 2014; 34:33-41 Spahr et al, PLoS One 2013; 8:e53719 Mohamadnejad et al, Liver Int 2013; 33:1490-1496 Xu et al, J Gastroenterol Hepatol 2014; 29:1620-1628

S410 www.painphysicianjournal.com